Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $85.67

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $86.50.

GPCR has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday. JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday. Finally, Morgan Stanley started coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price on the stock.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $27.90 on Friday. Structure Therapeutics has a 1 year low of $26.23 and a 1 year high of $62.74. The firm’s 50-day moving average is $35.32 and its 200-day moving average is $38.75. The company has a market cap of $1.60 billion, a P/E ratio of -37.70 and a beta of -3.41.

Institutional Trading of Structure Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can acquired a new position in shares of Structure Therapeutics during the second quarter valued at $1,064,000. Vestal Point Capital LP grew its position in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after buying an additional 590,000 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new position in Structure Therapeutics during the 2nd quarter valued at about $1,178,000. abrdn plc raised its position in shares of Structure Therapeutics by 132.7% during the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock worth $9,528,000 after buying an additional 123,789 shares in the last quarter. Finally, Pier Capital LLC lifted its stake in shares of Structure Therapeutics by 32.7% in the 3rd quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock worth $5,894,000 after acquiring an additional 33,087 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.